Nephrology Drugs Market Growth Outlook Through 2024-2033

Overview and Scope
Nephrology drugs, also known as renal drugs, refer to medicines related to kidney care. These drugs are often related to high blood pressure and hypertension. It is used to attempt to enhance kidney function and to slow the disease down, preventing it from doing further harm to the body.

Sizing and Forecast
The nephrology drugs market size has grown strongly in recent years. It will grow from $16.18 billion in 2023 to $17.08 billion in 2024 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to rising prevalence of chronic kidney diseases (ckd), advancements in drug development, increasing awareness and diagnosis, government initiatives and healthcare policies, increasing incidence of diabetes.

The nephrology drugs market size is expected to see strong growth in the next few years. It will grow to $21.53 billion in 2028 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to emerging therapies and drug innovations, precision medicine and personalized treatment approaches, increasing healthcare expenditure, telehealth and remote patient monitoring, global health initiatives. Major trends in the forecast period include collaborations and partnerships, technological advancements in dialysis, advancements in treatment modalities, growing emphasis on early diagnosis and intervention, technological integration in nephrology management.

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/nephrology-drugs-global-market-report

Segmentation & Regional Insights
The nephrology drugs market covered in this report is segmented –

1) By Drugs: Antihypertensive Agents, Erythropoiesis-Stimulating Agents, Diuretics, ACE Inhibitors, Antidiabetic Agents, Other Drugs
2) By Route Of Administration: Oral, Parenteral, Other Route Of Administration
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

North America was the largest region in the nephrology drug market in 2023. Europe will be the second-largest growing region in the nephrology drug market in 2023. The regions covered in the nephrology drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample_request?id=10076&type=smp

Major Driver Impacting Market Growth
The rising prevalence of chronic kidney disease is expected to propel the growth of the nephrology drugs market going forward. Chronic kidney disease (CKD) refers to damaged kidneys that are unable to filter blood as effectively as they should. because kidney damage develops gradually over a lengthy period of time. Wastes could accumulate in the body as a result of this injury. Nephrology drugs are primarily used in the treatment of chronic kidney disease to enhance kidney function and slow the disease, preventing it from doing more harm to the body, so these factors boost the nephrology drug market. For instance, in July 2022, according to reports shared by the Centers for Disease Control and Prevention (CDC), a US-based health protection agency, it was estimated that in the US, more than 37 million people were diagnosed with chronic kidney disease, which is more common in people aged 65 years or older (38 percent). Furthermore, according to the Kidney Foundation of Canada, a Canada-based non-profit organization, 4 million Canadians are suffering from kidney diseases. 35 percent of diabetic patients are the leading cause of kidney failure. These numbers are expected to rise in the future. Therefore, the rising prevalence of chronic kidney disease is driving the growth of the nephrology drug market.

Key Industry Players

Major companies operating in the nephrology drugs market report are AstraZeneca PLC, AbbVie Inc., Akebia Therapeutics Inc., Amgen Inc., F. Hoffmann-La Roche AG, FibroGen Inc., Johnson And Johnson, Pfizer Inc., GlaxoSmithKline PLC, Teva Pharmaceutical Industries Limited, Boehringer Ingelheim International GmbH, Reata Pharmaceuticals Inc., Ardelyx Inc., Novo Nordisk A/S, Novartis AG, Baxter International Inc., Bristol Myers Squibb Company, Kissei Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Mallinckrodt Pharmaceuticals, OPKO Health Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Vifor Pharma Group, Bayer AG, Amicus Therapeutics, Chugai Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Mylan N.V., Endo Pharmaceuticals plc

The nephrology drugs market report table of contents includes:

1. Executive Summary
2. Nephrology Drugs Market Characteristics
3. Nephrology Drugs Market Trends And Strategies
4. Nephrology Drugs Market – Macro Economic Scenario
5. Global Nephrology Drugs Market Size and Growth
.
.
.
31. Global Nephrology Drugs Market Competitive Benchmarking
32. Global Nephrology Drugs Market Competitive Dashboard
33. Key Mergers And Acquisitions In The Nephrology Drugs Market
34. Nephrology Drugs Market Future Outlook and Potential Analysis
35. Appendix

Explore the trending research reports from TBRC:

Email: [email protected]

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model